3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
4
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Breast Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiosurgery
6
Specimen Handling
5
Nivolumab
5
Ifosfamide
5
fludarabine phosphate
4
Mycophenolic Acid
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Busulfan
4
Sunitinib
3
Sirolimus
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Paclitaxel
3
Melphalan
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
Cyclosporine
3
Cryosurgery
3
Carboplatin
3
trastuzumab deruxtecan
2
tislelizumab
2
sargramostim
2
pazopanib
2
fludarabine
2
etoposide phosphate
2
cabozantinib
2
Whole-Body Irradiation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
entrectinib
×
Sarcoma
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA